Reactions 1478, p5 - 16 Nov 2013

★Adalimumab/etanercept

Atopic dermatitis (first report with adalimumab) inan elderly patient: case report

A 65-year-old woman developed atopic dermatitis (AD)following treatment with adalimumab and etanercept.

The woman had rheumatoid arthritis. She was using SCadalimumab 40mg [frequency not stated]. She developed anintense pruritic eczema in her flexures after 2 months.Eosinophilia and IgE elevation were seen on her blood tests.

Adalimumab was withdrawn, and the woman was treatedwith desonide. Her lesions disappeared. After 3 months, shestarted using etanercept [dosage and route not stated]. Shedeveloped new eczema lesions with eosinophilia [duration ofetanercept treatment to reaction onset not stated]. Etanerceptwas withdrawn. Her pruritus and AD lesions improved, andtotal control was achieved in 2 weeks.

Author comment: "AD is another rare side effect of theTNF-α inhibitors, such as adalimumab and etanercept."Pires MC, et al. Atopic dermatitis as a side effect of anti-TNFa. Dermatitis 24: 12,No. 4, Jul-Aug 2013. Available from: URL: http://dx.doi.org/10.1097/DER.0b013e31829ccfc5 [abstract] - Brazil 803095710

» Editorial comment: A search of AdisBase, Medline andEmbase did not reveal any previous case reports of atopicdermatitis associated with adalimumab. The WHO ADRdatabase contained 10 reports of dermatitis atopic associatedwith adalimumab.

1

Reactions 16 Nov 2013 No. 14780114-9954/13/1478-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved